Search on StockPrognosis.com
To search on the site stockprognosis.com enter the name of the ticker, company name, or search phrase
Sections of the site

JNJ Sentiment Analysis

We collect and analyze sentiment surrounding JNJ stock to help you make informed investment decisions.

JNJ

Johnson & Johnson's Innovative Healthcare Solutions

Published on October 2, 2025

Johnson & Johnson continues to lead the way in the healthcare industry with its innovative solutions....

JNJ

Johnson & Johnson: How Investors May Respond To JNJ Talc Verdict and New Medical Innovations

Published on August 10, 2025

Johnson & Johnson, a global healthcare company, has recently been in the spotlight due to controversies surrounding their talc products. Despite this setback, investors are keeping a close eye on the company's new medical innovations, which could pot...

JNJ

Johnson & Johnson Innovates with New Product Launches

Published on July 14, 2025

Johnson & Johnson, a leading pharmaceutical company, continues to make waves in the industry with its latest submission of sNDA for the schizophrenia drug CAPLYTA to the FDA. This move is expected to bring significant momentum to the company's stock,...

JNJ

Revolutionary Innovation: JNJ Johnson & Johnson Leads the Medical Industry with Groundbreaking Technology

Published on May 25, 2025

Johnson & Johnson, the renowned medical technology company, continues to be at the forefront of innovation in the industry....

JNJ

Johnson & Johnson Neurovascular leader heads for the exit

Published on March 21, 2025

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, has announced his departure from the company....

JNJ

Johnson & Johnson Faces Shareholder Activism Over Human Rights and Executive Pay Proposals

Published on March 20, 2025

Mark Dickinson, the leader of Johnson & Johnson Neurovascular, is leaving the company, according to sources....

JNJ

FDA Clears Johnson & Johnson Robot for Enhanced Bronchoscopy

Published on March 19, 2025

Johnson & Johnson's MedTech division has received clearance from the FDA for its enhanced robotic-assisted bronchoscopy system....

JNJ

Johnson & Johnson MedTech Introduces New EP Neurovascular Leader

Published on March 18, 2025

Johnson & Johnson MedTech, a subsidiary of Johnson & Johnson, has appointed a new leader for its electrophysiology and neurovascular group. The company aims to enhance its innovation and research in the field of neurovascular technologies and improve...

JNJ

Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments

Published on March 14, 2025

Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD). IBD is a chronic condition that affects millions of people worldwide and can lead to severe sympt...

JNJ

Johnson & Johnson's Strong Performance Since Last Earnings Report Raises Expectations

Published on February 28, 2025

Johnson & Johnson (JNJ) has shown an impressive 8....

JNJ

The surgical devices I design for JJ speed healing and save lives

Published on February 26, 2025

Johnson & Johnson (JNJ) has been at the forefront of medical technology, constantly innovating and developing breakthrough surgical devices that not only speed up the healing process but also save lives. The company's commitment to improving patient ...

JNJ

Johnson & Johnson reportedly wants to sell Cerenovus for 1B

Published on February 18, 2025

According to recent reports, Johnson & Johnson is considering selling its Cerenovus stroke business for 1 billion dollars....

JNJ

Johnson & Johnson Explores Sale of Cerenovus for $1 Billion

Published on February 16, 2025

According to reports, pharmaceutical giant Johnson & Johnson is looking to sell its stroke care business, Cerenovus, for a staggering $1 billion. The company is said to be focusing on its core business areas and streamlining its operations. Cerenovus...

JNJ

Johnson & Johnson to Sell its Cerenovus Stroke Business for $1B

Published on February 14, 2025

Johnson & Johnson, the multinational pharmaceutical company, is reportedly looking to sell its Cerenovus stroke care business for a sum of $1 billion. The decision comes as part of the company's strategy to streamline its portfolio and focus on its c...

JNJ

Johnson & Johnson Faces Scrutiny, CEO Welcomes Investigation

Published on February 4, 2025

Johnson & Johnson, the renowned healthcare company, is under scrutiny for alleged misconduct and product safety issues....

JNJ

JNJ Stock Forecast: What's Next for Johnson & Johnson after an Upbeat Q4?

Published on January 31, 2025

Johnson & Johnson (JNJ) recently reported strong financial results for the fourth quarter of 2024, surpassing analysts' expectations. The company's revenue increased by 10% compared to the previous year, driven by strong sales in its pharmaceutical a...

JNJ

Johnson & Johnson's 2024 Fourth-Quarter and Full-Year Earnings Report Revealed

Published on January 28, 2025

Johnson & Johnson (JNJ) has released its highly anticipated earnings report for the fourth quarter and full-year of 2024....

JNJ

JJ to buy psychiatric drug developer Intra-Cellular for 14.6B

Published on January 15, 2025

In a major move to bolster its presence in the mental health sector, pharmaceutical giant JNJ Johnson & Johnson has announced its acquisition of Intra-Cellular Therapies for a staggering $14.6 billion. This acquisition marks a significant expansion f...

JNJ

Johnson & Johnson Makes Major Neuro Play With $14.6B Intra-Cellular Buyout

Published on January 14, 2025

Johnson & Johnson, one of the world's largest pharmaceutical companies, has announced its acquisition of psychiatric drug developer Intra-Cellular. The deal, valued at $14.6 billion, marks a significant move for J&J into the field of neurology. The c...

JNJ

Johnson & Johnson Reports Significant Extension in Survival Rates for Lung Cancer Patients

Published on January 13, 2025

In a recent development, pharmaceutical giant Johnson & Johnson (JNJ) announced that its lung cancer drug has shown promising results in extending the survival rates of patients. The drug, which is currently undergoing clinical trials, has demonstrat...

JNJ

Johnson & Johnson's Lung Cancer Drug Significantly Extends Survival, Company Reports

Published on January 11, 2025

Johnson & Johnson (JNJ) has announced that its lung cancer drug has shown promising results in extending patient survival....

JNJ

Johnson & Johnson's Lung Cancer Drug Extends Survival, New Study Shows

Published on January 9, 2025

Johnson & Johnson announced today that its revolutionary lung cancer drug, known as Varipulse PFA, has significantly extended the survival of patients in a recent clinical trial. The study, conducted on a large patient population, showed a clear ...

JNJ

Johnson & Johnson Reports Strong Quarterly Earnings

Published on January 8, 2025

Johnson & Johnson (JNJ) announced its quarterly earnings today, showcasing impressive growth and beating analysts' expectations....

JNJ

Johnson & Johnson Declares Dividend; Short Interest Declines

Published on January 6, 2025

Johnson & Johnson (JNJ) has recently declared a dividend payout to its shareholders....

JNJ

Johnson & Johnson Reports Decline in Short Interest, Declares Dividend

Published on January 5, 2025

Johnson & Johnson, a multinational pharmaceutical company, recently declared its quarterly dividend and reported a decline in short interest. The company's dividend reflects its commitment to providing returns to its shareholders. Additionally, the d...